Tier 2 — strong

Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial

D A Shoskes, S I Zeitlin, A Shahed, J Rajfer
Urology 1999 54(6):960

Bibliography

PubMed
PMID 10604689
DOI
10.1016/s0090-4295(99)00358-1
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized double-blind placebo-controlled pilot with a separate open-label extension
ModelHuman intervention research
Sample30 men randomized; 28 evaluated; 17 additional men in the extension
InterventionQuercetin 500 mg twice daily; extension used a quercetin-containing enzyme combination
Duration1 month
EndpointsSymptoms and quality of life; Urinary or pelvic symptoms

What the study showed, in plain terms

Published in 1999, this source examined prostate and urinary health. Design: Randomized double-blind placebo-controlled pilot with a separate open-label extension. Sample/model: 30 men randomized; 28 evaluated; 17 additional men in the extension. The exposure or intervention was Quercetin 500 mg twice daily; extension used a quercetin-containing enzyme combination. Follow-up or treatment period: 1 month.

Chronic pelvic-pain symptom scores improved more with quercetin than placebo.

Small and short preliminary trial. The uncontrolled enzyme-combination extension should not be combined with the randomized sample or treated as equivalent evidence.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Prostatitis and Chronic Pelvic Pain. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Chronic pelvic-pain symptom scores improved more with quercetin than placebo.
  • The recorded outcome domains were Symptoms and quality of life; Urinary or pelvic symptoms.
  • The result applies to the tested exposure: Quercetin 500 mg twice daily; extension used a quercetin-containing enzyme combination; 1 month.

What this study can and cannot tell us

  • Small and short preliminary trial. The uncontrolled enzyme-combination extension should not be combined with the randomized sample or treated as equivalent evidence.
  • Without a sufficiently blinded concurrent control, time effects, expectations, co-interventions and regression toward the mean can explain part of an apparent improvement.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Oral Preparation of Hyaluronic Acid, Chondroitin Sulfate, Curcumin, and Quercetin (Ialuril® Soft Gels) for the Prevention of LUTS after Intravesical Chemotherapy
Celeste Manfredi et al. · Pathophysiology : the official journal of the International Society for Pathophysiology · 2022
Tier 2
Treatment of interstitial cystitis with a quercetin supplement
F Katske et al. · Techniques in urology · 2001

Citation network

Articles citing this research paper

5 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology